MannKind (MNKD) Competitors $3.76 -0.01 (-0.27%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$3.78 +0.02 (+0.40%) As of 06/27/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNKD vs. LGND, BCRX, FOLD, INVA, CLDX, DVAX, NVAX, OPK, GERN, and RGLSShould you be buying MannKind stock or one of its competitors? The main competitors of MannKind include Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Amicus Therapeutics (FOLD), Innoviva (INVA), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry. MannKind vs. Its Competitors Ligand Pharmaceuticals BioCryst Pharmaceuticals Amicus Therapeutics Innoviva Celldex Therapeutics Dynavax Technologies Novavax OPKO Health Geron Regulus Therapeutics MannKind (NASDAQ:MNKD) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk. Is MNKD or LGND more profitable? MannKind has a net margin of 10.12% compared to Ligand Pharmaceuticals' net margin of -73.07%. Ligand Pharmaceuticals' return on equity of -7.83% beat MannKind's return on equity.Company Net Margins Return on Equity Return on Assets MannKind10.12% -32.41% 10.85% Ligand Pharmaceuticals -73.07%-7.83%-6.92% Which has higher valuation & earnings, MNKD or LGND? MannKind has higher revenue and earnings than Ligand Pharmaceuticals. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMannKind$297.60M3.84$27.59M$0.1037.60Ligand Pharmaceuticals$167.13M13.18-$4.03M-$7.12-16.03 Do analysts recommend MNKD or LGND? MannKind currently has a consensus price target of $10.33, suggesting a potential upside of 174.82%. Ligand Pharmaceuticals has a consensus price target of $146.14, suggesting a potential upside of 28.03%. Given MannKind's stronger consensus rating and higher probable upside, equities analysts clearly believe MannKind is more favorable than Ligand Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MannKind 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Ligand Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer MNKD or LGND? In the previous week, MannKind had 1 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 8 mentions for MannKind and 7 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.90 beat MannKind's score of 0.62 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 1 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, MNKD or LGND? MannKind has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Do institutionals & insiders have more ownership in MNKD or LGND? 49.5% of MannKind shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 2.7% of MannKind shares are held by company insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryMannKind beats Ligand Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MNKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNKD vs. The Competition Export to ExcelMetricMannKindMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.14B$2.83B$5.45B$8.91BDividend YieldN/A2.70%5.35%4.14%P/E Ratio37.6021.1626.2419.67Price / Sales3.84278.29409.57112.35Price / Cash27.0941.2925.7827.49Price / Book-12.977.197.875.41Net Income$27.59M-$55.05M$3.16B$248.99M7 Day Performance-1.05%1.53%2.60%2.85%1 Month Performance-9.62%5.83%5.36%5.49%1 Year Performance-27.97%-0.74%31.74%16.97% MannKind Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNKDMannKind3.0555 of 5 stars$3.76-0.3%$10.33+174.8%-28.0%$1.14B$297.60M37.60400Analyst DowngradeHigh Trading VolumeLGNDLigand Pharmaceuticals4.7331 of 5 stars$115.01+2.2%$146.14+27.1%+35.5%$2.22B$181.49M45.8280BCRXBioCryst Pharmaceuticals4.438 of 5 stars$10.29-0.8%$16.56+60.9%+51.5%$2.15B$503.49M-16.87530Trending NewsAnalyst DowngradeGap UpFOLDAmicus Therapeutics3.9944 of 5 stars$6.05+0.3%$16.22+168.1%-40.2%$1.86B$543.14M-33.61480High Trading VolumeINVAInnoviva4.1166 of 5 stars$21.80+0.5%$55.00+152.3%+21.7%$1.37B$369.84M31.59100Positive NewsCLDXCelldex Therapeutics2.5802 of 5 stars$20.34-4.3%$50.90+150.2%-45.2%$1.35B$7.56M-7.91150Positive NewsDVAXDynavax Technologies4.3883 of 5 stars$10.17-1.0%$24.00+136.0%-11.8%$1.22B$294.62M56.50350Positive NewsNVAXNovavax4.4717 of 5 stars$7.03+1.3%$19.20+173.1%-49.7%$1.14B$1.21B-3.111,990OPKOPKO Health4.5134 of 5 stars$1.33flat$2.75+106.8%+5.6%$1.05B$689.41M-7.004,200GERNGeron3.0602 of 5 stars$1.55+2.6%$5.06+226.6%-64.9%$987.22M$116.29M-4.8470RGLSRegulus Therapeutics2.1843 of 5 stars$8.22+1.4%$8.50+3.4%N/A$569.10MN/A-7.6830Analyst UpgradeGap Up Related Companies and Tools Related Companies Ligand Pharmaceuticals Alternatives BioCryst Pharmaceuticals Alternatives Amicus Therapeutics Alternatives Innoviva Alternatives Celldex Therapeutics Alternatives Dynavax Technologies Alternatives Novavax Alternatives OPKO Health Alternatives Geron Alternatives Regulus Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNKD) was last updated on 6/30/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored“Trump’s 24-Hour Profit Windows” revealedTrading legend Larry Benedict has discovered a repeating surge of $240 billion (and more)... Flowing into a...Brownstone Research | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share MannKind With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MNKD Stock Alerts